Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IOVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIovance wins Australian approval for Amtagvi in advanced melanoma, third global market
Filed June 10, 2026 · Period ending June 4, 2026 · ~1 min read
Key Changes
-
high
Australia's TGA approved Amtagvi for previously treated advanced melanoma, marking the third global market authorization and first solid tumor T cell therapy in Australia, a country with the world's highest melanoma rate (17,000 new cases annually).
Exhibit 99.1 view on EDGAR → -
high
Shareholders approved increasing authorized common stock by 150M shares (from 500M to 650M), passing with 77.4% support and 21.7% opposition, providing equity capacity for future capital raises or acquisitions without immediate dilution.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
high
Company is establishing its first Australian treatment center as part of international expansion strategy targeting high-melanoma-prevalence markets, critical for generating revenue outside the U.S.
Exhibit 99.1 view on EDGAR → -
medium
Say-on-pay vote passed with 80.5% support, but 18.1% opposition is elevated compared to typical votes and may warrant board review of compensation structure or disclosure.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
All six directors elected with 91.0%–93.6% support; shareholders voted 94.3% for annual (vs. biennial or triennial) say-on-pay frequency going forward.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
Summary
Iovance secured its third global market authorization for Amtagvi, with Australia's Therapeutic Goods Administration approving the tumor-derived T cell therapy for previously treated advanced melanoma.
This is the first T cell therapy for a solid tumor cancer approved in Australia, a strategically important market given the country's world-leading melanoma incidence of approximately 17,000 new cases and 1,500 deaths annually. The approval, based on the C-144-01 Phase 2 trial with five-year follow-up data, positions Iovance to begin commercialization as it establishes its first Australian treatment center.
At the annual meeting, shareholders approved a 150-million-share increase in authorized common stock (from 500M to 650M shares), passing with 77.4% support. This provides the company with equity capacity for future capital raises, acquisitions, or employee compensation without triggering immediate dilution. The say-on-pay vote passed with 80.5% support, though the 18.1% opposition level is elevated and may prompt board attention to compensation practices. All governance proposals passed, with directors elected at 91%+ support and shareholders voting overwhelmingly for annual say-on-pay frequency going forward.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · verify on EDGAR →
the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of Amtagvi® (lifileucel), a tumor-derived autologous T cell immunotherapy, for previously treated advanced (metastatic or unresectable) melanoma. Amtagvi is indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
Australia's Therapeutic Goods Administration approved Amtagvi for treating advanced melanoma in patients who have already received anti-PD-1 therapy and, if applicable, targeted BRAF/MEK inhibitor therapy. This is the third market authorization for Amtagvi globally and represents the first T cell therapy approved for a solid tumor cancer in Australia. The approval addresses a significant unmet need in Australia, which has the world's highest melanoma rate with approximately 17,000 new cases and 1,500 deaths annually.
Added in current filing · view on EDGAR →
We are in the process of authorizing our first Australian treatment center as we advance our expansion strategy for Amtagvi in additional markets with a high prevalence of advanced melanoma.
Iovance is establishing its first treatment center in Australia as part of a broader international expansion strategy targeting markets with high melanoma prevalence. This operational milestone is critical for commercializing Amtagvi outside the U.S. and generating international revenue. The company's ability to scale manufacturing and treatment center authorization will determine the pace and success of global market penetration.
Added in current filing · view on EDGAR →
TGA granted approval based on safety and efficacy results from the global, multicenter C-144-01 trial investigating Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 therapy and targeted therapy, if applicable.
The Australian approval relies on data from the C-144-01 Phase 2 trial, which evaluated Amtagvi monotherapy in previously treated metastatic melanoma patients. Efficacy was measured by objective response rate and duration of response per RECIST criteria. Results from this trial were published in the Journal for ImmunoTherapy of Cancer in 2022, with five-year follow-up data published in the Journal of Clinical Oncology in 2025, providing a mature safety and efficacy dataset supporting the approval.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
IOVA held its 2026 annual meeting with 74% turnout; all seven proposals passed, including director elections and a 150M share authorization increase.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
At the Annual Meeting, 329,492,680 shares, or approximately 74% of all shares of the Company’s common stock outstanding as of the record date, were represented either in person or by proxy.
The annual meeting achieved a quorum with 329,492,680 shares represented, approximately 74% of outstanding shares. This turnout level is typical for biotech annual meetings and sufficient for all proposals to proceed to a vote.
Added in current filing · verify on EDGAR →
Proposal 3: This proposal was approved as follows: 188,106,776 “1 YEAR” votes, 3,404,958 “2 YEARS” votes, 3,558,800 “3 YEARS” votes, and 4,242,859 “ABSTAIN” votes. There were 0 broker non-votes in connection with this proposal.
Shareholders voted overwhelmingly for annual say-on-pay votes, with 94.3% selecting the 1-year frequency (1 Year votes divided by total votes cast excluding Abstain). This means future executive compensation votes will occur annually rather than every two or three years.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify